Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0I1BQ
|
|||
Former ID |
DCL000842
|
|||
Drug Name |
IL-18BP
|
|||
Indication | B-cell non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Discontinued in Phase 1 | [1] | |
Rheumatoid arthritis [ICD-11: FA20] | Discontinued in Phase 1 | [1] | ||
Company |
Yeda; Merck Serono
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Interleukin-18 (IL18) | Target Info | Binder | [2] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
NOD-like receptor signaling pathway | ||||
Cytosolic DNA-sensing pathway | ||||
Salmonella infection | ||||
Legionellosis | ||||
African trypanosomiasis | ||||
Malaria | ||||
Tuberculosis | ||||
Influenza A | ||||
Inflammatory bowel disease (IBD) | ||||
Rheumatoid arthritis | ||||
NetPath Pathway | IL4 Signaling Pathway | |||
Panther Pathway | Interleukin signaling pathway | |||
Toll receptor signaling pathway | ||||
Pathway Interaction Database | IL27-mediated signaling events | |||
IL12-mediated signaling events | ||||
IL23-mediated signaling events | ||||
Cellular roles of Anthrax toxin | ||||
IL12 signaling mediated by STAT4 | ||||
Reactome | Interleukin-1 processing | |||
WikiPathways | Hypertrophy Model | |||
IL1 and megakaryotyces in obesity | ||||
Corticotropin-releasing hormone | ||||
NOD pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013227) | |||
REF 2 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.